What is Koselugo (selumetinib)?
Koselugo is the brand name for selumetinib, a prescription medicine used to treat certain children and adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. The drug is designed to target cancer-driving signaling in tumor cells by inhibiting a pathway involved in growth.
Who is it for, and what does it treat?
Koselugo is used for patients with NF1 who have plexiform neurofibromas (abnormal growths involving nerves) that cause symptoms and cannot be removed with surgery (inoperable). These are typically described as “symptomatic” and “plexiform” in treatment eligibility criteria.
How does Koselugo work?
Selumetinib (Koselugo) is a “MEK inhibitor.” It blocks MEK proteins in the MAP kinase signaling pathway, which can be abnormally active in tumors, helping slow tumor growth and reduce tumor-related problems.
How is it taken?
Koselugo is taken orally (by mouth) as a capsule, with dosing based on body weight and prescribing information.
What do patients and caregivers usually ask about?
Common questions include what results to expect (such as shrinkage or symptom improvement for plexiform neurofibromas), how long treatment may be continued, and side effects and monitoring needs while on a MEK inhibitor.
Where can you check the drug’s status and patent details?
For updates related to Koselugo’s approval and related intellectual property, DrugPatentWatch.com is a useful reference point: https://www.drugpatentwatch.com/